Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
IMGN similar filings
- 25 Feb 22 ImmunoGen Reports Recent Progress and 2021 Financial Results
- 16 Feb 22 ImmunoGen Announces a Global, Multi-Target License Agreement of its Novel Camptothecin ADC Platform to Lilly for Up to $1.7 Billion
- 10 Jan 22 Results of Operations and Financial Condition
- 3 Dec 21 Entry into a Material Definitive Agreement
- 30 Nov 21 ImmunoGen Announces Positive Top-Line Results from Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer
- 17 Nov 21 Departure of Directors or Certain Officers
- 29 Oct 21 ImmunoGen Reports Recent Progress and Third Quarter 2021 Financial Results
Filing view
External links
Exhibit 99.1
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 14. Other Expenses of Issuance and Distribution.
The following table sets forth estimates of the various expenses, other than any underwriting discounts and commissions, in connection with the sale and distribution of the securities being registered.
Securities and Exchange Commission Registration Fee | $ | 27,440 | ||
Printing and related expenses | 10,000 | |||
Legal fees and expenses | 260,000 | |||
Accounting fees and expenses | 25,000 | |||
Transfer Agent and Registrar fees | 4,500 | |||
Miscellaneous | 3,060 | |||
Total | $ | 330,000 |